(Baccardax, 2/6) Reuters: AbbVie Raises 2027 Sales Forecast For New Immunology Drugs To $27 Billion AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous prediction. The Chicago-based drugmaker has been counting on revenues from its newer immunology medicines to help make up for declining sales of blockbuster arthritis drug Humira. (Leo and Wingrove, 2/2) Perspectives: Nothing Can Stop Another Drug Debacle Like Aduhelm Read recent commentaries about pharmaceutical issues. Stat: The Biogen Aduhelm Mess Could Happen Again Last week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer's disease. Its decision, the company explained, is not a response to new data about the drug's safety or efficacy, but instead "a reprioritization of resources." Simply put, it wasn't about science or medicine. It was about money.